AVI BioPharma (AVII) -31.8% premarket after saying a 24-week study showed its eteplirsen drug...

|By:, SA News Editor

AVI BioPharma (AVII) -31.8% premarket after saying a 24-week study showed its eteplirsen drug had a statistically significant effect in raising the level of a key protein, dystrophin, in boys with Duchenne muscular dystrophy, but patients given the drug for only 12 weeks showed no significant increase despite receiving higher doses. (PR)